BioWorld-International-2007-10-24

No Abstract

No Abstract

No Abstract

No Abstract

No Abstract

Paion AG gave its beleaguered investors a little autumnal cheer by raising hopes that its clot-busting stroke drug Desmoteplase might return to the clinic, despite a Phase III clinical trial miss earlier this year that precipitated a share price plunge. (BioWorld International)

No Abstract

No Abstract

No Abstract